{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:57:22Z","timestamp":1778284642817,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s00595-008-3826-3","type":"journal-article","created":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T11:30:22Z","timestamp":1236771022000},"page":"194-200","source":"Crossref","is-referenced-by-count":32,"title":["Innate immune therapy with a Bacillus Calmette-Gu\u00e9rin cell wall skeleton after radical surgery for non-small cell lung cancer: A case-control study"],"prefix":"10.1007","volume":"39","author":[{"given":"Ken","family":"Kodama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Higashiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Takami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Okami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misako","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Seya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumao","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,12]]},"reference":[{"key":"3826_CR1","first-page":"505","volume-title":"Basic science of oncology","author":"N.L. Berinstein","year":"2005","unstructured":"Berinstein NL. Biological therapy of cancer. In: Tannock IF, Hill RP, Bristow RG, Harrington L, editors. Basic science of oncology. New York: McGraw-Hill; 2005. p. 505\u2013539."},{"key":"3826_CR2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","volume":"5","author":"A. Iwasaki","year":"2004","unstructured":"Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987\u2013995.","journal-title":"Nat Immunol"},{"key":"3826_CR3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev.iy.12.040194.002005","volume":"12","author":"T. Boon","year":"1994","unstructured":"Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337\u2013365.","journal-title":"Annu Rev Immunol"},{"key":"3826_CR4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"S.A. Rosenberg","year":"2004","unstructured":"Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909\u2013915.","journal-title":"Nat Med"},{"key":"3826_CR5","first-page":"4369","volume":"23","author":"T. Seya","year":"2003","unstructured":"Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K. Role of Toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 2003;23: 4369\u20134376.","journal-title":"Anticancer Res"},{"key":"3826_CR6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm1589","volume":"13","author":"H. Kanzler","year":"2007","unstructured":"Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552\u2013559.","journal-title":"Nat Med"},{"key":"3826_CR7","first-page":"21","volume":"10","author":"T. Parkinson","year":"2008","unstructured":"Parkinson T. The future of Toll-like receptor therapeutics. Curr Opin Mol Ther 2008;10:21\u201331.","journal-title":"Curr Opin Mol Ther"},{"key":"3826_CR8","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1128\/IAI.68.12.6883-6890.2000","volume":"68","author":"S. Tsuji","year":"2000","unstructured":"Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Gu\u00e9rin: involvement of Toll-like receptors. Infect Immun 2000;68:6883\u20136890.","journal-title":"Infect Immun"},{"key":"3826_CR9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/0008-5472.CAN-03-1518","volume":"64","author":"T. Akazawa","year":"2004","unstructured":"Akazawa T, Masuda H, Saeki Y, Matsumoto M, Takeda K, Tsujimura K, et al. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res 2004;64:757\u2013764.","journal-title":"Cancer Res"},{"key":"3826_CR10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/oxfordjournals.jjco.a023194","volume":"26","author":"A. Hayashi","year":"1996","unstructured":"Hayashi A, Noda A. Does the cell wall skeleton from Bacille Calmette-Gu\u00e9rin directly induce interferon-gamma, independent of interleukin-12? Jpn J Clin Oncol 1996;26:124\u2013127.","journal-title":"Jpn J Clin Oncol"},{"key":"3826_CR11","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/IAI.71.8.4238-4249.2003","volume":"71","author":"J. Uehori","year":"2003","unstructured":"Uehori J, Matsumoto M, Tsuji S, Akazawa T, Takeuchi O, Akira S, et al. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Gu\u00e9rin peptidoglycan. Infect Immun 2003;71:4238\u20134249.","journal-title":"Infect Immun"},{"key":"3826_CR12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2183\/pjab.74.50","volume":"74","author":"A. Hayashi","year":"1998","unstructured":"Hayashi A, Doi O, Azuma I, Toyoshima K. Immuno-friendly use of BCG-cell-wall skeleton remarkably improves the survival rate of various cancer patients. Proc Japan Acad 1998;74:50\u201355.","journal-title":"Proc Japan Acad"},{"key":"3826_CR13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1348-0421.1971.tb00569.x","volume":"15","author":"I. Azuma","year":"1971","unstructured":"Azuma I, Kishimoto S, Yamamura Y, Petit JF. Adjuvancity of mycobacterial cell wall. Jpn J Microbiol 1971;15:193\u2013197.","journal-title":"Jpn J Microbiol"},{"key":"3826_CR14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2183\/pjab.75.295","volume":"75","author":"A. Hayashi","year":"1999","unstructured":"Hayashi A, Nakamura H, Sugihara T, Azuma I. BCG-cell wall skeleton completely cures the immunologically eligible acute leukemia patients. Proc Japan Acad 1999;75:295\u2013300.","journal-title":"Proc Japan Acad"},{"key":"3826_CR15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00205355","volume":"14","author":"T. Ochiai","year":"1983","unstructured":"Ochiai T, Sato H, Hayashi R, Asano T, Sato H, Yamamura Y. Postoperative adjuvant immunotherapy of gastric cancer with BCG-CWS wall skeleton. 3- to 6-year follow-up of a randomized clinical trial. Cancer Immunol Immunother 1983;14:167\u2013171.","journal-title":"Cancer Immunol Immunother"},{"key":"3826_CR16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","volume":"311","author":"Non-Small Cell Lung Cancer Collaborate Group.","year":"1995","unstructured":"Non-Small Cell Lung Cancer Collaborate Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899\u2013909.","journal-title":"BMJ"},{"key":"3826_CR17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E.L. Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Sat Assoc 1958;53:457\u2013481.","journal-title":"J Am Sat Assoc"},{"key":"3826_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2183\/pjab.70.205","volume":"70","author":"A. Hayashi","year":"1994","unstructured":"Hayashi A. Interferon-\u03b3 as a marker for the effective cancer immunotherapy with BCG-cell wall skeleton. Proc Japan Acad 1994;70:205\u2013209.","journal-title":"Proc Japan Acad"},{"key":"3826_CR19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev.iy.12.040194.002005","volume":"12","author":"T. Boon","year":"1994","unstructured":"Boon T, Cerottini J-C, Van Der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337\u2013365.","journal-title":"Annu Rev Immunol"},{"key":"3826_CR20","first-page":"213","volume":"46","author":"I. Barao","year":"1998","unstructured":"Barao I, Ascensao JL. Human natural killer cells. Arch Immunol Ther Exp 1998;46:213\u2013229.","journal-title":"Arch Immunol Ther Exp"},{"key":"3826_CR21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1078-0432.361.11.1","volume":"11","author":"K.A. Mason","year":"2005","unstructured":"Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, et al. Targeting Toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005;11:361\u2013369.","journal-title":"Clin Cancer Res"},{"key":"3826_CR22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1158\/1078-0432.7.11.1","volume":"11","author":"G.K. Koski","year":"2005","unstructured":"Koski GK, Czerniecki BJ. Combining innate immunity with radiation therapy for cancer treatment. Clin Cancer Res 2005;11: 7\u201311.","journal-title":"Clin Cancer Res"},{"key":"3826_CR23","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.165.3.1228","volume":"165","author":"G.B. Lipford","year":"2000","unstructured":"Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 2000;165:1228\u20131235.","journal-title":"J Immunol"},{"key":"3826_CR24","first-page":"1559","volume":"1","author":"M. Matsumoto","year":"2001","unstructured":"Matsumoto M, Seya T, Kikkawa S, Tsuji S, Shida K, Nomura M, et al. Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int Immunol 2001;1: 1559\u20131569.","journal-title":"Int Immunol"},{"key":"3826_CR25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0092-8674(94)90332-8","volume":"76","author":"W.E. Paul","year":"1994","unstructured":"Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241\u2013251.","journal-title":"Cell"},{"key":"3826_CR26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2003.11.004","volume":"44","author":"A. Trojan","year":"2004","unstructured":"Trojan A, Urosevic M, Dummer R, Giger R, Weder W, Stahel RA. Immune activation status of CD8+ T cells infi ltrating non-small cell lung cancer. Lung Cancer 2004;44:143\u2013147.","journal-title":"Lung Cancer"},{"key":"3826_CR27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00595-007-3578-5","volume":"37","author":"F. Tanaka","year":"2007","unstructured":"Tanaka F. UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon\/rectum, and breast): clinical evidence, mechanism of action, and future direction. Surg Today 2007;37:923\u2013943.","journal-title":"Surg Today"},{"key":"3826_CR28","first-page":"3262","volume":"39","author":"K. Yasumoto","year":"1979","unstructured":"Yasumoto K, Manabe H, Yanagawa E, Nagano N, Ueda H, Hirota N, et al. Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin. Cancer Res 1979;39:3262\u20133267.","journal-title":"Cancer Res"},{"key":"3826_CR29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(90)90601-A","volume":"60","author":"K.M. Cull","year":"1990","unstructured":"Cull KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Halber DA, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms\u2019 tumor locus. Cell 1990;60:509\u2013520.","journal-title":"Cell"},{"key":"3826_CR30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/jjco\/hyl005","volume":"36","author":"S. Morita","year":"2006","unstructured":"Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, et al. A phase I\/II trial of a WT1 (Wilms\u2019 tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 2006;36:231\u2013236.","journal-title":"Jpn J Clin Oncol"},{"key":"3826_CR31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00262-003-0498-0","volume":"53","author":"H. Nakajima","year":"2004","unstructured":"Nakajima H, Kawasaki K, Oka Y, Tsuboi A, Kawakami M, Ikegame K, et al. WT1 peptide vaccination combined with BCGCWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 2004;53:617\u2013624.","journal-title":"Cancer Immunol Immunother"},{"key":"3826_CR32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(98)07186-4","volume":"353","author":"J.B. Vermorken","year":"1999","unstructured":"Vermorken JB, Claessen MEC, Van Tinteren H, Gall HE, Ezinga R, Meijer S, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet 1999;353: 345\u2013350.","journal-title":"Lancet"},{"key":"3826_CR33","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(04)01610-9","volume":"5","author":"S. Mocellin","year":"2004","unstructured":"Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Vaccines for solid tumours. Lancet Oncol 2004;5:681\u2013689.","journal-title":"Lancet Oncol"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-008-3826-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00595-008-3826-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-008-3826-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T10:19:40Z","timestamp":1684923580000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00595-008-3826-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["3826"],"URL":"https:\/\/doi.org\/10.1007\/s00595-008-3826-3","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}